Under CEO Dave Ricks, Eli Lilly cut drug development timelines from 13–14 years to around 5 years, exemplified by the speedy development of tirzepatide (Mounjaro/Zepbound).
Snapshot · Bloomberg Intelligence
Under CEO Dave Ricks, Eli Lilly cut drug development timelines from 13–14 years to around 5 years, exemplified by the speedy development of tirzepatide (Mounjaro/Zepbound).
Where this was said
At 29:18 · chapter starts 28:38
Madison Muller details how CEO Dave Ricks made speed Eli Lilly's number-one priority, cutting drug development from 13–14 years to 5, and piloted this approach with tirzepatide. [1] — Madison Muller "When Dave Ricks took over as CEO, Eli Lilly was one of the slowest drug developers in the industry. He mandated speed above all else. The r…" 28:38
When Dave Ricks took over as CEO, Eli Lilly was one of the slowest drug developers in the industry. He mandated speed above all else. The result: tirzepatide went from lab to approval in about 5 years — less than half the old timeline.
Eli Lilly is deploying its GLP-1 windfall into internal R&D, acquisitions, and AI — including a partnership with NVIDIA and an on-site supercomputer. The question is whether AI can actually deliver new drugs before Lilly's patents expire.
Despite predictions that AI would eliminate radiologists, the Mayo Clinic's radiology staff grew 55% after AI arrived at reading scans.
In 2025, radiology was the second-highest paid medical specialty in America, with average incomes 48% higher than a decade ago.
A study across 3 hospitals found radiologists spent only 36% of their time reading scans — the part AI can do — with the rest being human judgment.
Robert Greene notes that one in six Americans is on some form of drug to deal with depression, suggesting a deep societal disconnection from meaningful experience.
Spencer Greenberg and Jeremy Stevenson analyzed almost 500 self-improvement techniques and found they all reduce to just 12 underlying psychological drivers.
Cold exposure has good short-term alertness benefits but the evidence base for long-term health benefits is much weaker than popularly believed.
In a randomized study of 20 habit-formation techniques run on hundreds of people, almost none of the techniques produced statistically meaningful results.
People given a tiny-habit fallback option (e.g. 10 squats instead of gym) were actually MORE successful at completing the full habit, not less.
The most effective habit-formation technique was 'habit reflection' — recalling a past successful habit, writing down what helped, then applying those lessons to a new habit.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.